Zymeworks (ZYME) Misses Q2 EPS by 25c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts ZYME Hot Sheet
Join SI Premium – FREE
Zymeworks (NASDAQ: ZYME) reported Q2 EPS of ($0.62), $0.25 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $4.6 million versus the consensus estimate of $19.1 million.
For earnings history and earnings-related data on Zymeworks (ZYME) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primis Financial (FRST) Misses Q3 EPS by 7c
- L'Oreal SA (OR:FP) (LRLCY) PT Raised to EUR450 at Goldman Sachs
- Burke & Herbert Bank & Trust Company (BHRB) Tops Q3 EPS by 9c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
